Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma

Posted in Uncategorized

The study tested paxalisib's effectiveness in patients whose genetic profile confers resistance to the only other treatment available for this condition. Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA), a cancer-focused drug development company based in Sydney, has released final data from its Phase 2 clinical study of the drug paxalisib – a first-line therapy in patients with glioblastoma.

Read More